Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

Advances in ‘omics’ technology and targeted therapeutic molecules are together driving the incorporation of molecular-based diagnostics into the care of patients with cancer. There is an urgent need to assess the efficacy of therapy determined by molecular matching of patients with particular target...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2015-08, Vol.26 (8), p.1791-1798
Hauptverfasser:	Rodon, J., Soria, J.C., Berger, R., Batist, G., Tsimberidou, A., Bresson, C., Lee, J.J., Rubin, E., Onn, A., Schilsky, R.L., Miller, W.H., Eggermont, A.M., Mendelsohn, J., Lazar, V., Kurzrock, R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - economics Antineoplastic Agents - supply & distribution Antineoplastic Agents - therapeutic use biomarker Canada clinical trials Clinical Trials as Topic - economics Clinical Trials as Topic - legislation & jurisprudence Clinical Trials as Topic - methods France Gene Expression Profiling Genomics Humans Israel Molecular Targeted Therapy - methods Neoplasms - drug therapy Neoplasms - metabolism Original personalized cancer therapy Precision Medicine - methods Prospective Studies Spain United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!